AstraZeneca plc (LON:AZN) received a GBX 4,200 ($54.69) target price from analysts at J P Morgan Chase & Co in a note issued to investors on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target would indicate a potential downside of 5.12% from the company’s previous close.

AZN has been the topic of a number of other reports. Morgan Stanley restated an “overweight” rating and set a GBX 5,600 ($72.93) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Thursday, May 4th. Barclays PLC restated an “overweight” rating and set a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Liberum Capital restated a “buy” rating and set a GBX 5,500 ($71.62) target price on shares of AstraZeneca plc in a report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 4,932.67 ($64.24).

Shares of AstraZeneca plc (LON:AZN) opened at 4426.50 on Wednesday. The company’s 50 day moving average is GBX 4,972.77 and its 200 day moving average is GBX 4,859.70. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The company’s market capitalization is GBX 56.04 billion.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) PT Set at GBX 4,200 by J P Morgan Chase & Co” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/11/astrazeneca-plc-lonazn-pt-set-at-gbx-4200-by-j-p-morgan-chase-co.html.

In other news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.